S&P 500   3,128.21 (-3.03%)
DOW   27,081.36 (-3.15%)
QQQ   215.37 (-2.72%)
AAPL   288.08 (-3.39%)
FB   196.77 (-1.97%)
MSFT   168.07 (-1.65%)
GOOGL   1,386.32 (-2.36%)
AMZN   1,972.74 (-1.82%)
CGC   19.62 (-3.35%)
NVDA   262.05 (-4.11%)
BABA   205.61 (-0.27%)
MU   52.10 (-5.29%)
GE   11.32 (-4.55%)
TSLA   799.91 (-4.06%)
AMD   47.57 (-3.16%)
T   37.35 (-1.84%)
ACB   1.51 (-2.58%)
F   7.23 (-4.49%)
NFLX   360.09 (-2.34%)
BAC   31.08 (-5.04%)
DIS   128.19 (-3.62%)
GILD   70.10 (-3.84%)
S&P 500   3,128.21 (-3.03%)
DOW   27,081.36 (-3.15%)
QQQ   215.37 (-2.72%)
AAPL   288.08 (-3.39%)
FB   196.77 (-1.97%)
MSFT   168.07 (-1.65%)
GOOGL   1,386.32 (-2.36%)
AMZN   1,972.74 (-1.82%)
CGC   19.62 (-3.35%)
NVDA   262.05 (-4.11%)
BABA   205.61 (-0.27%)
MU   52.10 (-5.29%)
GE   11.32 (-4.55%)
TSLA   799.91 (-4.06%)
AMD   47.57 (-3.16%)
T   37.35 (-1.84%)
ACB   1.51 (-2.58%)
F   7.23 (-4.49%)
NFLX   360.09 (-2.34%)
BAC   31.08 (-5.04%)
DIS   128.19 (-3.62%)
GILD   70.10 (-3.84%)
S&P 500   3,128.21 (-3.03%)
DOW   27,081.36 (-3.15%)
QQQ   215.37 (-2.72%)
AAPL   288.08 (-3.39%)
FB   196.77 (-1.97%)
MSFT   168.07 (-1.65%)
GOOGL   1,386.32 (-2.36%)
AMZN   1,972.74 (-1.82%)
CGC   19.62 (-3.35%)
NVDA   262.05 (-4.11%)
BABA   205.61 (-0.27%)
MU   52.10 (-5.29%)
GE   11.32 (-4.55%)
TSLA   799.91 (-4.06%)
AMD   47.57 (-3.16%)
T   37.35 (-1.84%)
ACB   1.51 (-2.58%)
F   7.23 (-4.49%)
NFLX   360.09 (-2.34%)
BAC   31.08 (-5.04%)
DIS   128.19 (-3.62%)
GILD   70.10 (-3.84%)
S&P 500   3,128.21 (-3.03%)
DOW   27,081.36 (-3.15%)
QQQ   215.37 (-2.72%)
AAPL   288.08 (-3.39%)
FB   196.77 (-1.97%)
MSFT   168.07 (-1.65%)
GOOGL   1,386.32 (-2.36%)
AMZN   1,972.74 (-1.82%)
CGC   19.62 (-3.35%)
NVDA   262.05 (-4.11%)
BABA   205.61 (-0.27%)
MU   52.10 (-5.29%)
GE   11.32 (-4.55%)
TSLA   799.91 (-4.06%)
AMD   47.57 (-3.16%)
T   37.35 (-1.84%)
ACB   1.51 (-2.58%)
F   7.23 (-4.49%)
NFLX   360.09 (-2.34%)
BAC   31.08 (-5.04%)
DIS   128.19 (-3.62%)
GILD   70.10 (-3.84%)
Log in

NASDAQ:NEOS - Neos Therapeutics Stock Price, Forecast & News

$1.52
-0.04 (-2.56 %)
(As of 02/25/2020 04:00 PM ET)
Today's Range
$1.48
Now: $1.52
$1.62
50-Day Range
$1.37
MA: $1.58
$1.88
52-Week Range
$1.13
Now: $1.52
$3.62
Volume243,720 shs
Average Volume265,684 shs
Market Capitalization$75.59 million
P/E RatioN/A
Dividend YieldN/A
Beta0.94
Neos Therapeutics, Inc, a pharmaceutical company, develops, manufactures, and commercializes products for the treatment of attention deficit hyperactivity disorder (ADHD) using its drug delivery technology platform. Its products are extended-release (XR) medications in orally disintegrating tablets or liquid suspension dosage forms. The company manufactures and markets Adzenys XR-ODT amphetamine for the treatment of ADHD; Cotempla XR-ODT methylphenidate for treating of ADHD; Adzenys ER amphetamine to treat ADHD; and generic Tussionex hydrocodone and chlorpheniramine for cough and upper respiratory symptoms of a cold. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:NEOS
CUSIPN/A
Phone972-408-1300

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$49.99 million
Book Value$0.16 per share

Profitability

Net Income$-51,670,000.00

Miscellaneous

Employees215
Market Cap$75.59 million
Next Earnings Date3/12/2020 (Estimated)
OptionableOptionable

Receive NEOS News and Ratings via Email

Sign-up to receive the latest news and ratings for NEOS and its competitors with MarketBeat's FREE daily newsletter.


Neos Therapeutics (NASDAQ:NEOS) Frequently Asked Questions

What is Neos Therapeutics' stock symbol?

Neos Therapeutics trades on the NASDAQ under the ticker symbol "NEOS."

How were Neos Therapeutics' earnings last quarter?

Neos Therapeutics Inc (NASDAQ:NEOS) released its quarterly earnings results on Friday, November, 8th. The company reported ($0.04) EPS for the quarter, topping the Thomson Reuters' consensus estimate of ($0.11) by $0.07. The company earned $17.54 million during the quarter. Neos Therapeutics had a negative return on equity of 2,087.24% and a negative net margin of 35.77%. View Neos Therapeutics' Earnings History.

When is Neos Therapeutics' next earnings date?

Neos Therapeutics is scheduled to release their next quarterly earnings announcement on Thursday, March 12th 2020. View Earnings Estimates for Neos Therapeutics.

What price target have analysts set for NEOS?

2 equities research analysts have issued twelve-month target prices for Neos Therapeutics' stock. Their forecasts range from $3.00 to $10.00. On average, they expect Neos Therapeutics' share price to reach $6.50 in the next year. This suggests a possible upside of 327.6% from the stock's current price. View Analyst Price Targets for Neos Therapeutics.

What is the consensus analysts' recommendation for Neos Therapeutics?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Neos Therapeutics in the last year. There are currently 1 hold rating and 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Neos Therapeutics.

Has Neos Therapeutics been receiving favorable news coverage?

News articles about NEOS stock have trended very negative this week, InfoTrie Sentiment Analysis reports. The research firm rates the sentiment of news coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Neos Therapeutics earned a media sentiment score of -3.0 on InfoTrie's scale. They also assigned headlines about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the stock's share price in the immediate future. View News Stories for Neos Therapeutics.

Who are some of Neos Therapeutics' key competitors?

What other stocks do shareholders of Neos Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Neos Therapeutics investors own include Exelixis (EXEL), Fibrocell Science (FCSC), Progenics Pharmaceuticals (PGNX), TG Therapeutics (TGTX), Verastem (VSTM), Synergy Pharmaceuticals (SGYP), SCYNEXIS (SCYX), Amicus Therapeutics (FOLD), T2 Biosystems (TTOO) and Agile Therapeutics (AGRX).

Who are Neos Therapeutics' key executives?

Neos Therapeutics' management team includes the folowing people:
  • Mr. Richard I. Eisenstadt, CFO, Treasurer & Corp. Sec. (Age 61)
  • Mr. Gerald W. McLaughlin, CEO, Pres & Director (Age 51)
  • Mr. John P. Limongelli, Sr. VP & Gen. Counsel (Age 49)
  • Mr. Darren Heath, VP of Sales
  • Mr. Russ McMahen, Sr. VP of R&D

When did Neos Therapeutics IPO?

(NEOS) raised $60 million in an initial public offering on Thursday, July 23rd 2015. The company issued 4,000,000 shares at a price of $14.00-$16.00 per share. UBS Investment Bank, BMO Capital Markets and RBC Capital Markets acted as the underwriters for the IPO and JMP Securities was co-manager.

Who are Neos Therapeutics' major shareholders?

Neos Therapeutics' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Goldman Sachs Group Inc. (5.15%), Renaissance Technologies LLC (1.34%), Russell Investments Group Ltd. (1.17%), Boston Partners (0.46%), Jacobs Levy Equity Management Inc. (0.24%) and Hunter Associates Investment Management LLC (0.20%). Company insiders that own Neos Therapeutics stock include Alan L Heller, Gerald W Mclaughlin and Richard I Eisenstadt. View Institutional Ownership Trends for Neos Therapeutics.

Which institutional investors are selling Neos Therapeutics stock?

NEOS stock was sold by a variety of institutional investors in the last quarter, including Oxford Asset Management LLP, Algert Global LLC, State Street Corp and Alambic Investment Management L.P.. View Insider Buying and Selling for Neos Therapeutics.

Which institutional investors are buying Neos Therapeutics stock?

NEOS stock was acquired by a variety of institutional investors in the last quarter, including Russell Investments Group Ltd., Renaissance Technologies LLC, Boston Partners, Goldman Sachs Group Inc., Jacobs Levy Equity Management Inc., Hunter Associates Investment Management LLC, BCS Wealth Management and Virtu Financial LLC. Company insiders that have bought Neos Therapeutics stock in the last two years include Alan L Heller, Gerald W Mclaughlin and Richard I Eisenstadt. View Insider Buying and Selling for Neos Therapeutics.

How do I buy shares of Neos Therapeutics?

Shares of NEOS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Neos Therapeutics' stock price today?

One share of NEOS stock can currently be purchased for approximately $1.52.

How big of a company is Neos Therapeutics?

Neos Therapeutics has a market capitalization of $75.59 million and generates $49.99 million in revenue each year. The company earns $-51,670,000.00 in net income (profit) each year or ($1.60) on an earnings per share basis. Neos Therapeutics employs 215 workers across the globe.View Additional Information About Neos Therapeutics.

What is Neos Therapeutics' official website?

The official website for Neos Therapeutics is http://www.neostx.com/.

How can I contact Neos Therapeutics?

Neos Therapeutics' mailing address is 2940 N. HIGHWAY 360, GRAND PRAIRIE TX, 75050. The company can be reached via phone at 972-408-1300 or via email at [email protected]


MarketBeat Community Rating for Neos Therapeutics (NASDAQ NEOS)

Community Ranking:  3.1 out of 5 (star star star)
Outperform Votes:  475 (Vote Outperform)
Underperform Votes:  290 (Vote Underperform)
Total Votes:  765
MarketBeat's community ratings are surveys of what our community members think about Neos Therapeutics and other stocks. Vote "Outperform" if you believe NEOS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NEOS will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/25/2020 by MarketBeat.com Staff

Featured Article: Sell-Side Analysts

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel